301015 百洋医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入5,627,105-8.41%8,094,4588,255,9987,509,6187,051,567
减:营业总成本4,964,392-5.49%7,169,3377,256,7826,832,0166,502,550
    其中:营业成本3,523,550-10.79%5,220,6605,507,1525,424,8745,279,724
               财务费用78,37537.35%71,10965,61348,38561,340
               资产减值损失(41,010)377.33%(16,023)1,911(1,160)2,596
公允价值变动收益74,113-1,308.05%1,716616(10,750)5,874
投资收益(6,155)-116.21%59,20944,5911,8773,900
    其中:对联营企业和合营企业的投资收益(4,409)-111.96%51,12118,87415,60117,182
营业利润706,473-22.49%977,7381,043,604674,258561,482
利润总额695,289-23.42%966,6281,027,991668,550565,418
减:所得税费用134,675-38.04%199,597257,263178,709150,403
净利润560,614-18.82%767,031770,728489,841415,016
减:非控股权益84,18569.80%75,43758,667(16,757)(6,626)
股东净利润476,429-25.67%691,593712,061506,598421,642

市场价值指针
每股收益 (元) *0.910-25.41%1.3201.3600.9600.850
每股派息 (元) *----0.7620.7620.7620.667
每股净资产 (元) *4.5317.74%4.3294.8874.3844.107
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容